News Hub | News Direct

Healthcare

Addiction Biotech Cannabis Genetics Healthcare Medical Devices Pharmaceutical Science Veterinary
Article thumbnail News Release

Immunic Inc eyeing "big step" for multiple sclerosis patients

Immunic Inc

Immunic Inc (NASDAQ:IMUX) president and CEO Dr Daniel Vitt joined Thomas Warner from Proactive ahead of World Brain Day to provide an update on the biotechnology company's novel multiple sclerosis (MS) treatment. Dr Vitt gives an overview of the treatment that Immunic is currently working on, and emphasisedsthe significance of addressing the high unmet medical need for MS patients worldwide. Immunic's focus is on developing a new therapeutic option, using vidofludimus calcium, to treat both relapsing and progressive forms of MS. He says that the drug is the first known modulator of the "so-called Nurr1 target", making it a potential neuroprotective treatment. Immunic is conducting a phase two clinical study into its treatment for progressive MS, with biomarker data expected in the second half of the year. Dr Vitt says registration studies for relapsing MS are progressing well, with an interim analysis anticipated next year. He adds that the MS market holds significant potential due to demand for treatments that strike a good balance between being both effective and tolerable, and says that "if we could confirm in the phase three study that the drug really prevents disability worsening that would be a big step for patients." Contact Details Proactive United States +1 347-449-0879 action@proactiveinvestors.com

July 25, 2023 08:00 AM Eastern Daylight Time

Video
Article thumbnail News Release

hVIVO signs second bespoke human challenge model contract in as many months

hVIVO PLC

hVIVO PLC (AIM:HVO) chief executive Mo Khan speaks to Thomas Warner from Proactive after announcing that the specialist contract research organisation has begun work on a new Flu B human challenge model as part of a new deal with an existing "large pharma" client company. Khan lays out the timeline for the rest of the work on the contract, suggesting that the "whole manufacturing process" should be complete by the end of Q3, at which point a characterisation study will begin. He adds that if the characterisation study is successful then he hopes the "full blown" human challenge trial can begin in the new year. Khan goes on to describe the potential impact of the model as "quite significant", highlighting some additional funding from the client to help expedite the process. He concludes by saying that hVIVO "is here to build new challenge models to be able to test new drugs and bring new vaccines to the market... overall we are very happy that we're adding a new human challenge model [and] very happy that we're continuing to help our current clients in bringing vaccines to market faster." Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

July 25, 2023 07:38 AM Eastern Daylight Time

Video
Article thumbnail News Release

Faron Pharmaceuticals hoping for first filing of BLA in H1 2025

Faron Pharmaceuticals Oy

Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) Chief Medical Officer Marie-Louise Fjällskog speaks to Thomas Warner from Proactive after releasing an update on progress with the clinical stage biopharmaceutical company's phase I/II BEXMAB study. Fjällskog gives an overview of the update, highlighting several "very nice objective responses" to Bexmarilimab treatment and saying that the data "just confirms that we have some very exciting things going on with our combination." One patient has now stayed on the treatment for 13 months, the company noted in its update. Looking further down the line, Faron said that it expects to file the first Biologics License Application (BLA) to US Food and Drug Administration (FDA) planned by the first half of 2025. Fjällskog also mentions that the company is currently active in recruiting more patients for its study and is opening more sites in the US and potentially in Europe to aid with the effort. Bexmarilimab, a novel anti-Clever-1 humanised antibody, is Faron's investigative precision immunotherapy with the potential to provide permanent immune stimulation for difficult-to-treat cancers through targeting myeloid function. Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

July 25, 2023 06:56 AM Eastern Daylight Time

Video
Article thumbnail News Release

Shield Therapeutics "really starting to fire on all cylinders"

Shield Therapeutics PLC

Shield Therapeutics PLC (AIM:STX, OTCQX:SHIEF) CEO Greg Madison speaks to Thomas Warner from Proactive after the commercial-stage specialty pharmaceutical company released a business update containing plenty of new information about its performance during the second quarter. Madison gives an overview of the update, highlighting strong US sales growth for its Accrufer/Feraccru iron deficiency treatment as a result of the commercial expansion with Viatris that was completed in May, which brought the combined sales team to 100 people. He stresses that the team is "really starting to fire on all cylinders" but "hasn't really hit full stride yet...I think there's more that we can do and we're constantly looking at how we tweak the business and what adjustments we can make to further that growth - but [we're] off to a really nice start." He also mentions a new marketing campaign and the addition of Andy Hurley as Chief Commercial Officer, who he describes as a "veteran on the commercial side... I couldn't be more pleased with his performance." Contact Details Proactive UK Ltd +44 20 7989 0813 uk@proactiveinvestors.com

July 25, 2023 06:45 AM Eastern Daylight Time

Video
Article thumbnail News Release

Doceree bolsters strategy building efforts with latest appointment as company seeks all-round global growth

Doceree Inc

Doceree, a leading global platform building solutions for healthcare professionals (HCPs) through programmatic messaging with proprietary data tools, today announced appointment of Kate Miller as Executive Vice President- Strategy in its bid to give the company a strategic uplift across functions and markets, and strengthen its presence in the pharma messaging space, globally. Kate will be responsible for driving key company and functional level strategies to ensure long term growth for Doceree. The appointment comes at a time when the company is aiming to launch some critical industry-first products and features on both supply and demand side that will have immense potential to change the face of current programmatic messaging landscape. An accomplished digital transformation leader with 25 years of experience in shaping digital marketing and digital innovation strategies and solutions for the life sciences industry, with the goal of enabling quantifiable business impact and meaningful customer value, Kate is passionate about translating innovative solutions and concepts into commercially viable strategies with demonstrated impact and repeatable learnings. “Doceree has expanded in terms of both markets and products to suit the unique needs of category stakeholders across various markets. At this stage of growth, we require sharp business and brand-focused strategies that could catapult our brand value in the industry,” said Harshit Jain MD, Founder & Global CEO, Doceree. “We are excited to onboard Kate at a time when she can with her expertise and experience direct us to embrace meaningful changes that can positively impact our business and growth. We look forward to seeing her implement industry-focused learnings to strategic initiatives here and shape Doceree’s future growth trajectory.” Prior to joining Doceree, Kate served as Chief Strategy Officer at Evolution Road, a leading digital marketing and innovation strategic consultancy. She also held roles as Practice Leader and Vice President of Innovation Commercialization. Earlier in her career, Kate worked for Cadient Group (now Cognizant) and Harte-Hanks Interactive, providing digital strategic planning services to pharmaceutical clients. “When I decided it was time to transition from Evolution Road after 15 fantastic years, I wanted to focus my exploration on maturing start-ups in the industry. My professional passion is helping organizations meet strategic objectives that unlock long-term growth,” said Kate Miller. “I was very impressed with Doceree's tremendous growth over the past 3 years, and with the vision, energy and passion that Harshit and his leadership team have for building new solutions to meet the needs of healthcare providers. I am excited to work with, learn from and solve new challenges with this awesome and dynamic team.” About Doceree Doceree is a global platform building unprecedented solutions for HCP programmatic messaging with proprietary data tools. It facilitates messaging between life sciences brands and HCPs through an extensive global network of digital endemic and point-of-care platforms to programmatically deliver personalized communications to physicians and transparent marketing campaign metrics at scale. To learn more, please visit https://doceree.com/ Contact Details Priyanka Bhasin +91 78387 03702 priyanka.bhasin@doceree.com Company Website https://doceree.com/us/

July 24, 2023 07:33 AM Eastern Daylight Time

Image
Article thumbnail News Release

RocketFuel announces agreement with Poncho Brotherz to accept cryptocurrency in its retail store

RocketFuel Blockchain

Rocketfuel Payment Solutions CEO Peter Jensen joined Steve Darling from Proactive to announce an exciting collaboration with Poncho Brotherz, a family-owned and operated farm-to-retail cannabis store. The collaboration aims to enable Poncho Brotherz to accept cryptocurrency payments at their dispensary, representing a significant step forward in embracing the digital currency revolution. Jensen explained that RocketFuel's innovative blockchain technology will empower Poncho Brotherz customers to make purchases using over 160 different cryptocurrencies, including well-known ones like Bitcoin. This new payment option not only simplifies the checkout process but also enhances security and privacy compared to traditional payment methods. The crypto solution provided by RocketFuel can be used both for online and in-store transactions, giving customers greater flexibility in their payment choices. By introducing cryptocurrency payments, Poncho Brotherz aims to stay ahead in the rapidly evolving cannabis retail space and cater to the growing number of customers who are adopting digital currencies. RocketFuel's solution provides a seamless and secure way to facilitate these transactions, enhancing the overall customer experience for cryptocurrency users at Poncho Brotherz dispensaries. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

July 21, 2023 12:43 PM Eastern Daylight Time

Video
Article thumbnail News Release

New Data Reveals Enforcement Alone Will Not Solve New York’s Gray Market Cannabis Problem

NuggMD

The recent headline-making raids by law enforcement designed to end illicit cannabis sales in New York are unlikely to work, according to a new, first-of-its-kind survey, because New Yorkers overwhelmingly trust the products they are purchasing in those locations. The survey was conducted by NuggMD, the nation’s leading telehealth platform for cannabis, and first reported by Cultivated, a cannabis newsletter written by Jeremy Berke, an independent journalist who formerly covered the cannabis industry for Insider. According to the survey, 61 percent of respondents who buy cannabis in unlicensed gray market locations said they trust that it has been tested for contaminants, while 22 percent of these respondents indicated they do not trust the safety of gray market products, but that they can’t purchase cannabis anywhere else. (Gray market locations do not have testing requirements.) Additionally, most respondents who purchase cannabis in the gray market reported one or more negative experiences with the products purchased. Thirty percent of these respondents said it made them higher than they expected, while 31 percent said the product looked, smelled, or tasted odd and 65 percent said the product didn’t get them as high as they expected, given the dose they consumed. Most concerning is that nearly 8 percent of respondents reported feeling unwell after consuming cannabis purchased in the gray market. “Our survey shows New Yorkers have an alarming amount of trust in the illicit cannabis products they’re purchasing from unlicensed retail locations. While this trust is misplaced, that doesn’t make it any less real, which is why enforcement alone is not a solution to the state’s illicit cannabis problem,” said Alex Milligan, co-founder and CMO of NuggMD. “So long as consumers trust those products, there will be demand for them.” While New York State legalized recreational cannabis more than two years ago, there are currently just 20 licensed recreational dispensaries open in the state, according to the Office of Cannabis Management. Five are clustered in one three-mile radius in Manhattan, and half have opened during the past two months. According to the NuggMD survey, individuals who hold medical cards were less likely to shop for cannabis in the gray market. Taken together, the data suggests that a combination of more licensed dispensaries and a public information campaign that emphasizes the difference between safe, lab-tested cannabis and cannabis bought in the gray market would slow the consumption of gray-market products and contribute meaningfully to public health and safety. Milligan concluded: “We know that it is difficult to regulate this sector while allowing operators to build a vibrant marketplace. But, as our survey shows, every barrier that impedes new licensed dispensaries from opening quickly where there is demand for them increases risk for many thousands of New Yorkers.” Methodology NuggMD sent a series of questions about cannabis buying patterns and preferences to approximately 70,000 cannabis consumers in New York State and received 354 responses. The survey is non-scientific and contains selection bias. The company hopes the survey prompts further study and ultimately reduces the barriers that impede more licensed recreational dispensaries from opening. About NuggMD NuggMD is the nation's leading medical marijuana technology platform, serving patients in California, Connecticut, Georgia, Illinois, Iowa, Maine, Maryland, Massachusetts, Michigan, Missouri, Montana, Nevada, New Jersey, New York, Ohio, Oklahoma, Pennsylvania, Texas, Vermont, Virginia, and West Virginia. They've connected over 1,000,000 patients face-to-face with their new medical marijuana doctors via their state-of-the-art telemedicine platform. They believe every human being has the right to explore the benefits of medical cannabis and are fully committed to helping each patient explore every option in their journey to wellness. For further information, visit NuggMD.com. Contact Details NuggMD Andrew Graham +1 646-385-0189 andrew.g@getnugg.com Company Website http://www.nuggmd.com

July 20, 2023 05:05 PM Eastern Daylight Time

Article thumbnail News Release

BioVie issues letter to shareholders; highlights latest update on NE3107 for Alzheimer's Disease

BioVie Inc

BioVie Inc CEO Cuong Do joined Steve Darling from Proactive to provide an update to shareholders on the company's progress in developing innovative drug therapies for advanced liver disease, as well as neurological and neurodegenerative disorders. In a letter to shareholders, BioVie Inc shared exciting updates and outlined their upcoming plans. Do informed Proactive that the Phase 3 trial for NE3107 in Alzheimer's Disease has been fully enrolled since February 2023 and is approaching completion by the end of September. The company eagerly anticipates releasing data from this trial later this year. BioVie Inc believes that the data obtained thus far suggest that NE3107 has the potential to reduce epigenetic changes caused by inflammation. Additionally, the company believes that NE3107 may be effective in reducing inflammation and oxidative stress, restoring homeostatic regulation, and facilitating the recovery of gene expression. These effects may improve neuronal health and potentially lead to better clinical measures of mild cognitive impairment and Alzheimer's Disease. Furthermore, BioVie Inc suggests that the changes observed in NE3107 treatment may indicate broad and multisystemic regulatory activities related to the diagnosis and progression of cognitive disorders, MCI, and dementia. The company is excited about the potential impact of NE3107 on these conditions. BioVie Inc remains committed to advancing their drug development efforts and improving the lives of patients with advanced liver disease and neurological disorders. The upcoming release of Phase 3 trial data for NE3107 in Alzheimer's Disease represents a significant milestone in their pursuit of innovative therapies. Contact Details Proactive Investors +1 347-449-0879 na-editorial@proactiveinvestors.com

July 20, 2023 01:06 PM Eastern Daylight Time

Video
Article thumbnail News Release

Avricore Health announces company will add blood glucose meters to HealthTab Platform

Avricore Health

Avricore Health CEO Hector Bremner joined Steve Darling from Proactive to share news about the company's collaboration with Ascensia Diabetes Care, a global diabetes care company and a subsidiary of PHC Holdings Corporation. Avricore Health has entered into an agreement with Ascensia Diabetes Care to integrate their blood glucose monitoring systems, known as CONTOUR®NEXT GEN and CONTOUR®NEXT ONE, with Avricore's pharmacy-based point-of-care testing platform, HealthTab. Bremner explained that this collaboration aims to provide better support to pharmacists in Canada to help them manage diabetes more effectively. By linking the daily blood glucose testing results and pattern history data collected via the CONTOUR®NEXT GEN or CONTOUR®NEXT ONE meter that the patient uses to the patient's HealthTab account, pharmacists will have access to valuable data insights for better patient care. The partnership also includes discussions on collaborative communications to ensure patients and pharmacists can take full advantage of the data insights offered by both technologies. The goal is to enhance patient engagement and improve diabetes management through the seamless integration of the blood glucose monitoring systems and HealthTab. Contact Details Proactive Studio +1 347-449-0879 na-editorial@proactiveinvestors.com

July 20, 2023 12:26 PM Eastern Daylight Time

Video
1 ... 5859606162 ... 210